<DOC>
	<DOCNO>NCT00662220</DOCNO>
	<brief_summary>Optimal ribavirin dosages essential achieve SVR ( sustained virological response ) . Several study show high SVR rate patient receive high dos ribavirin . Therefore propose randomize control open label multicenter trial investigate wether high ( 25-29mg/kg ) dose ribavirin improve outcome patient infect hepatitis C virus genotype 1 4 compare standard dose ( 12-15mg/kg ) .</brief_summary>
	<brief_title>High-dose Ribavirin Treatment Chronic Hepatitis C Genotype 1 4</brief_title>
	<detailed_description>Optimal ribavirin dosages essential achieve SVR . The initial evidence support high dos ribavirin peginterferon alfa-2b come secondary analysis pivotal multicenter trial peginterferon alfa-2b ribavirin . Patients receive 10.6 mg/kg/day ribavirin experience significantly high SVR rate ( 48 % vs. 38 % ) . A large multicenter trial design test standard dose ribavirin ( 1000-1200 mg/day ) versus low-dose ribavirin ( 800 mg/day ) combination peginterferon alfa-2a , show 52 % SVR standard dose group versus 41 % low-dose group genotype 1 infected patient . In pooled data two pivotal study peginterferon alfa-2a ribavirin , probability achieve SVR genotype 1 patient influenced ribavirin dose per kg body weight . A 40-50 % increase probability SVR find 12-16 mg/kg dose increase ribavirin . For peginterferon alfa-2b also show among genotype 1 patient , weight-based ribavirin ( 800-1400 mg/day ) lead high SVR rate compare fix dose ribavirin ( 800 mg/day ) ( 34 % vs. 29 % ) . Moreover , ribavirin dosing 1400 mg/day safe rate treatment discontinuation treatment group . In small pilot study , 10 genotype 1 patient high baseline load treat peginterferon alfa-2a individualize high-dose ribavirin order achieve ribavirin target concentration serum 15 μmol/l . The mean ribavirin dose 2540 mg/day ( range 1600-3600 mg/day ) high , result 90 % SVR . All patient experience severe anemia , treat concomitant epoetin beta blood transfusion . As mentioned , main concern high-dose ribavirin dose-dependent hemolytic anemia addition epoetin alfa show significant increase haemoglobin ( peg ) interferon/ribavirin therapy . Erythropoietin dose 9,000 60,000 IU/week use order keep high possible ribavirin dos . A recent trial show significant high SVR rate genotype 1 patient treated peginterferon alfa-2b , increase dose ribavirin ( 15.2 mg/kg/day ) epoetin alfa patient treat peginterferon alfa-2b standard dose ribavirin ( 13.3 mg/kg/day ) without epoetin alfa . Using standard ribavirin dose , routine use erythropoietin significantly decrease frequency anemia mean ribavirin dose reduction . Moreover , addition erythropoietin , significant high mean dose could give patient increase ribavirin dose arm .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>hepatitis C genotype 1 4 high viral load ( &gt; 400000 IU/ml ) indication antiviral treatment patient 's desire antiviral treatment hepatitis C treatment naive liver biopsy within 3 year screen visit biopsy contraindicate e.g patient clot disease patient refuse undergo new biopsy case liver biopsy old 3 year , substitution fibroscan allow . age 1870 year serum bilirubin &gt; 35 μmol/l albumin &lt; 36 g/l prothrombin time &gt; 4 sec prolong platelet &lt; 90x109/l decompensated cirrhosis ( ChildPugh Grade B C ) hepatic imaging ( ultrasound , CT MRI ) evidence hepatocellular carcinoma ( hepatic imaging perform within 3 month prior screen cirrhotic patient within 6 month prior screen noncirrhotic patient ) alcoholic liver disease ( indicator : MCV &gt; 100 ) obesity induce liver disease ( indicator : steatosis proven biopsy ultrasound association body mass index &gt; 30 ) drug relate liver disease ( indicator : positive history hepatic toxic drug intake causal relation ) autoimmune hepatitis ( indicator : IgG &gt; 30g/l , anti smoothmuscle antinuclear antibody titer ³1:40 ) hemochromatosis ( indicator : ferritin &gt; 1000 μg/l ) Wilson 's disease ( indicator : ceruloplasmin ( &lt; 0.2 g/l ) alpha1 antitrypsin deficiency ( indicator alpha1 antitrypsin &lt; 0.8 g/L ) coinfection hepatitis B virus human immunodeficiency virus ( HIV ) cardiovascular dysfunction ( e.g . cardiac decompensation , myocardial infarction , present history arrythmia ) medical illness might interfere study : significant pulmonary renal dysfunction , malignancy skin basocellular carcinoma previous 5 year , immunodeficiency syndrome ( e.g . : steroid therapy , organ transplant cornea hair transplant ) contraindication peginterferon and/or ribavirin : severe psychiatric disorder , major psychosis , suicidal ideation , suicidal attempt and/or manifest depression . Severe depression would include follow : ( ) subject hospitalized depression , ( b ) subject receive electroconvulsive therapy depression , ( c ) subject whose depression result prolonged absence work and/or significant disruption daily function . Subjects history mild depression may consider entry protocol provide pretreatment assessment subject 's mental status support subject clinically stable ongoing evaluation patient 's mental status study visual symptom relate retinal abnormality pregnancy , breastfeed inadequate contraception thalassemia , spherocytosis female pregnant intend become pregnant male partner female pregnant intend become pregnant absolute neutrophil count ( ANC ) &lt; 1.40x109/l hemoglobin ( Hb ) &lt; 7.5 mmol/l ( female ) &lt; 8.1 mmol/l ( male ) serum creatinine concentration &gt; 1.5 time upper limit normal screen substance abuse , I.V . drug alcohol ( indicator : &gt; 28 drinks/week ) . If subject history substance abuse , consider inclusion protocol , subject must abstain use abused substance least 1 year condition opinion investigator would make patient unsuitable enrollment , could interfere patient participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>chronic</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>ribavirin</keyword>
	<keyword>SVR</keyword>
	<keyword>genotype one</keyword>
	<keyword>genotype four</keyword>
</DOC>